Triptolide, an active compound identified in a traditional Chinese herb, induces apoptosis of rheumatoid synovial fibroblasts

BMC Pharmacology

Volumn 4, Issue , 2004, Pages

  Kusunoki, Natsuko ^a   Yamazaki, Ryuta ^a,b   Kitasato, Hidero ^c   Beppu, Moroe ^a   Aoki, Haruhito ^a   Kawai, Shinichi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CASPASE; CASPASE 3; CASPASE INHIBITOR; DNA FRAGMENT; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN DERIVATIVE; TETRAZOLE DERIVATIVE; TRIPTERYGIUM WILFORDII EXTRACT; TRIPTOLIDE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CHINESE HERB; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG ANALYSIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MEASUREMENT; NICK END LABELING; PLASMID; RECEPTOR UPREGULATION; REPORTER GENE; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

APOPTOSIS; ARTHRITIS, RHEUMATOID; CASPASES; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; DITERPENES; DRUGS, CHINESE HERBAL; EPOXY COMPOUNDS; FIBROBLASTS; HUMANS; PHENANTHRENES; SYNOVIAL MEMBRANE; TRIPTERYGIUM;

EID: 2642520514     PISSN: 14712210     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2210-4-2     Document Type: Article

References (41)

1. Lipsky PE, Tao XL: A potential new treatment for rheumatoid arthritis: thunder god vine. Semin Arthritis Rheum 1997, 26:713-723.
2. Tao X, Cush JJ, Garret M, Lipsky PE: A phase I study of ethyl acetate extract of the Chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid arthritis. J Rheumatol 2001, 28:2160-2167.
3. Tao X, Younger J, Fan FZ, Wang B, Lipsky PE: Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2002, 46:1735-1743.
4. Asano K, Matsuishi J, Yu Y, Kasahara T, Hisamitsu T: Suppressive effects of Tripterygium wilfordii Hook f., a traditional Chinese medicine, on collagen arthritis in mice. Immunopharmacology 1998, 39:117-126.
5. Tao X, Ma L, Mao Y, Lipsky PE: Suppression of carrageenan-induced inflammation in vivo by an extract of the Chinese herbal remedy Tripterygium wilfordii Hook F. Inflamm Res 1991, 48:139-148.
6. Ho LJ, Chang DM, Chang ML, Kuo SY, Lai JH: Mechanism of immunosuppression of the antirheumatic herb TWHf in human T cells. J Rheumatol 1999, 26:14-24.
7. Chang DM, Chang WY, Kuo SY, Chang ML: The effects of traditional antirheumatic herbal medicines on immune response cells. J Rheumatol 1997, 24(3):436-441.
8. Chou CT, Chang SC: The inhibitory effect of common traditional anti-rheumatic herb formulas on prostaglandin E and interleukin 2 in vitro: a comparative study with Tripterygium wilfordii. J Ethnopharmacol 1998, 62:167-171.
9. Maekawa K, Yoshikawa N, Du J, Nishida S, Kitasato H, Okamoto K, Tanaka H, Mizushima Y, Kawai S: The molecular mechanism of inhibition of interleukin-1beta-induced cyclooxygenase-2 expression in human synovial cells by Tripterygium wilfordii Hook F extract. Inflamm Res 1999, 48:575-581.
10. Tao X, Cai JJ, Lipsky PE: The identity of immunosuppressive components of the ethyl acetate extract and chloroform methanol extract (T2) of Tripterygium wilfordii Hook. F. J Pharmacol Exp Ther 1995, 272:1305-1312.
11. Gu WZ, Chen R, Brandwein S, McAlpine J, Burres N: Isolation, purification, and characterization of immunosuppressive compounds from tripterygium: triptolide and tripdiolide. Int J Immunopharmacol 1995, 17:351-356.
12. Yang Y, Liu Z, Tolosa E, Yang J, Li L: Triptolide induces apoptotic death of T lymphocyte. Immunopharmacology 1998, 40:139-149.
13. Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, Ng JC, Kao PN: Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 1999, 274:13443-13450.
14. Hu KB, Liu ZH, Liu D, Li LS: Inhibition of vascular endothelial growth factor expression and production by triptolide. Planta Med 2002, 68:368-369.
15. Liu H, Liu ZH, Chen ZH, Yang JW, Li LS: Triptolide: a potent inhibitor of NF-kappa B in T-lymphocytes. Acta Pharmacol Sin 2000, 21:782-786.
16. Tao X, Schulze-Koops H, Ma L, Cai J, Mao Y, Lipsky PE: Effects of Tripterygium wilfordii hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis Rheum 1998, 41:130-138.
17. Lin N, Sato T, Ito A: Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f., suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human synovial fibroblasts. Arthritis Rheum 2001, 44:2193-2200.
18. Chen BJ: Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma 2001, 42:253-265.
19. Gu WZ, Brandwein SR: Inhibition of type II collagen-induced arthritis in rats by triptolide. Int J Immunopharmacol 1998, 20:389-400.
20. Zhao G, Vaszar LT, Qiu D, Shi L, Kao PN: Anti-inflammatory effects of triptolide in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2000, 279:L958-966.
21. Zvaifler NJ, Firestein GS: Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 1994, 37:783-789.
22. Nishioka K, Hasunuma T, Kato T, Sumida T, Kobata T: Apoptosis in rheumatoid arthritis: A novel pathway in the regulation of synovial tissue. Arthritis Rheum 1998, 41:1-9.
23. Eguchi K: Apoptosis in autoimmune diseases. Intern Med 2001, 40:275-284.
24. Kawakami A, Nakashima T, Sakai H, Hida A, Urayama S, Yamasaki S, Nakamura H, Ida H, Ichinose Y, Aoyagi T, Furuichi I, Nakashima M, Migita K, Kawabe Y, Eguchi K: Regulation of synovial cell apoptosis by proteasome inhibitor. Arthritis Rheum 1999, 42:2440-2448.
25. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V: Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001, 44:1984-1992.
26. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999, 353:259-266.
27. Stennicke HR, Salvesen GS: Caspases - controlling intracellular signals by protease zymogen activation. Biochim Biophys Acta 2000, 1477:299-306.
28. Li H, Zhu H, Xu CJ, Yuan J: Cleavage of BID by caspase-8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491-501.
29. Jiang XH, Wong BC, Lin MC, Zhu GH, Kung HF, Jiang SH, Yang D, Lam SK: Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene 2001, 20:8009-8018.
30. Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF, Yang J, Underhill CB, Zhang L: Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003, 2:65-72.
31. Lee KY, Chang W, Qiu D, Kao PN, Rosen GD: PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem 1999, 274:13451-13455.
32. Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC, Schmid RA: PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 2003, 22:5427-5435.
33. Kawahito Y, Kondo M, Tsubouchi Y, Hashiramoto A, Bishop-Bailey D, Inoue K, Kohno M, Yamada R, Hla T, Sano H: 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000, 106:189-197.
34. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S: Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor g in rheumatoid synovial fibroblasts. J Pharmacol Exp Ther 2002, 302:18-25.
35. Kusunoki N, Yamazaki R, Kawai S: Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase-2 inhibitors. Arthritis Rheum 2002, 46:3159-3167.
36. Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T, Mizushima Y: Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol 1998, 347:87-94.
37. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
38. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
39. Shuman S: Structure, mechanism, and evolution of the mRNA capping apparatus. Prog Nucleic Acid Res Mol Biol 2001, 66:1-40.
40. Marcus SL, Miyata KS, Zhang B, Subramani S, Rachubinski RA, Capone JP: Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes, but differentially induce expression. Proc Natl Acad Sci USA 1993, 90:5723-5727.
41. Tontonoz P, Hu E, Graves RA, Budavari Al, Spiegelman BM: mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994, 8:1224-1234.